Biography for Ryan McBride
Ryan McBride is an award-winning journalist who writes about the life sciences industry. Prior to joining FierceMarkets, he was a freelance journalist and served as a correspondent at Xconomy for more than two years. His stories have appeared in The Boston Globe, the Boston Business Journal, The Motley Fool, and many other publications. In recent years, he has also given guest lectures to graduate students at Boston University’s Center for Science & Medical Journalism. Earlier in his career, he held staff reporter positions at Mass High Tech, Providence Business News, and The Westerly Sun. Ryan enjoys spending time with his family and exploring mountains and beaches in New England. Follow Ryan on Twitter at @RyanMFierce or send him e-mail here.
Articles by Ryan McBride
Biogen Idec has taken steps to provide a strong and durable fortress around intellectual property for its potential blockbuster Tecfidera in the European Union, but the effort is going to require additional time.
Biogen Idec's ($BIIB) newly approved Tecfidera has a wholesale price of $54,900 per year, the biotech giant revealed on Friday. With the U.S. market debut of the oral multiple sclerosis drug set for Monday, Biogen plans to hit the market for MS pills with a lower price than Novartis' ($NVS) Gilenya, which is arguably the company's top competition.
Vivus ($VVUS) has taken a pounding on Wall Street with the lackluster debut of its closely watched weight-loss drug Qsymia, as the company fell short of analysts' big expectations for the launch of one of the first new diet pills to hit the U.S. market in years. Now Vivus CEO Leland Wilson has pledged to do better at managing expectations for the ongoing launch, Cowen analysts noted after a meeting with Wilson in New York on Wednesday.
Sanofi boss Chris Viehbacher isn't limiting his global drug giant's emerging market opportunities to China and India--or any of the four BRIC countries for that matter. In an interview with Bloomberg, the Sanofi CEO made known that he sees growth opportunities in spots such as Colombia, Indonesia and Vietnam.
So begins the court hearing that major pharma outfits with blockbuster ambitions in India are watching. Novartis has initiated its argument for the patentability of its hit cancer drug Gleevec in India at the start of a hearing on Tuesday in country's high court, Reuters reported.
Pharma is betting that a picture can be worth a thousand words (or Tweets?) in the world of the social web, with a growing number of major drugmakers raising flags on Pinterest, the social photo-sharing website that attracts millions of monthly visitors, PMLive reports.
ThromboGenics came closer to having its first approved drug on the U.S. market, gaining an FDA advisory committee recommendation for its lead drug candidate, ocriplasmin, for combatting vision-impairing vitreomacular adhesion.
With drugmakers flocking to lucrative drug markets for specialty care drugs, the bar has risen to get reimbursement and physician uptake of the expensive products. But there are ways to hedge bets in the specialty care game. We covered several such strategies during a panel I moderated at the 2012 BIO International Convention called "Are Healthcare Reimbursement Policies a Barrier to Specialty Care Treatment?" The easy answer to this question is "yes."
Novartis CEO Joe Jimenez has a new answer to his critics in Switzerland, where the drug giant's major layoff plans ignited a wave of protests against the company.
An Israel-based team of researchers has found an uptick in eye ailments in teens and young adults taking Roche's anti-acne med isotretinoin.